MEK targeting in N-RAS mutated metastatic melanoma

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Thumar, Jaykumar ^a   Shahbazian, David ^a   Aziz, Saadia A ^a   Jilaveanu, Lucia B ^a   Kluger, Harriet M ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Apoptosis; MEK inhibitor; Melanoma; N RAS; Targeted therapy

Indexed keywords

ARRY 438162; B RAF KINASE; CHIR 265; DABRAFENIB; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROPIDIUM IODIDE; VEMURAFENIB;

ADULT; AGED; APOPTOSIS; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER PROGNOSIS; CELL SURVIVAL; CLONOGENIC ASSAY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MIDDLE AGED; ONCOGENE N RAS; RETROSPECTIVE STUDY; SURVIVAL RATE; WESTERN BLOTTING;

AGED; BENZIMIDAZOLES; BLOTTING, WESTERN; FEMALE; GENES, RAS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAP KINASE KINASE KINASES; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; TUMOR CELLS, CULTURED;

EID: 84896732424     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-45     Document Type: Article

References (36)

1. Liu LS, Colegio OR. Molecularly targeted therapies for melanoma. Int J Dermatol 2013, 52:523-530. 10.1111/j.1365-4632.2012.05829.x, 23590367.
2. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62:6997-7000.
3. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003, 63:756-759.
4. Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118:4014-4023. 10.1002/cncr.26724, 3310961, 22180178.
5. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, Chin L. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012, 18:1503-1510. 10.1038/nm.2941, 3777533, 22983396.
6. Yeh I, von Deimling A, Bastian BC. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. J Natl Cancer Inst 2013, 105:917-919. 10.1093/jnci/djt119, 23690527.
7. Birkeland E, Busch C, Berge EO, Geisler J, Jonsson G, Lillehaug JR, Knappskog S, Lonning PE. Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Clin Exp Metastasis 2013, 30(7):867-76. 10.1007/s10585-013-9587-4, 3837233, 23673558.
8. Safaee Ardekani G, Jafarnejad SM, Khosravi S, Martinka M, Ho V, Li G. Disease progression and patient survival Are significantly influenced by BRAF protein expression in primary melanoma. Br J Dermatol 2013, 169(2):320-8. 10.1111/bjd.12351, 23550516.
9. Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM. Advances in therapy for melanoma brain metastases. Clin Dermatol 2013, 31:264-281. 10.1016/j.clindermatol.2012.08.008, 23608446.
10. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005, 65:2412-2421. 10.1158/0008-5472.CAN-04-2423, 15781657.
11. Furge KA, Kiewlich D, Le P, Vo MN, Faure M, Howlett AR, Lipson KE, Woude GF, Webb CP. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci U S A 2001, 98:10722-10727. 10.1073/pnas.191067898, 58533, 11535809.
12. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819. 10.1056/NEJMoa1002011, 3724529, 20818844.
13. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012, 11:873-886. 10.1038/nrd3847, 23060265.
14. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365. 10.1016/S0140-6736(12)60868-X, 22735384.
15. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-114. 10.1056/NEJMoa1203421, 22663011.
16. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008, 9:517-531. 10.1038/nrm2438, 3915522, 18568040.
17. Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007, 129:865-877. 10.1016/j.cell.2007.05.018, 17540168.
18. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nat Rev Cancer 2010, 10:842-857. 10.1038/nrc2960, 3124093, 21102635.
19. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, Wittinghofer A. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997, 277:333-338. 10.1126/science.277.5324.333, 9219684.
20. Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist 2005, 10:565-578. 10.1634/theoncologist.10-8-565, 16177281.
21. Casey PJ, Solski PA, Der CJ, Buss JE. p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci U S A 1989, 86:8323-8327. 10.1073/pnas.86.21.8323, 298273, 2682646.
22. Gajewski DN TF, Johnson J, Linette G, Bucher C, Blaskovich M, Sebti S, Haluska F. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104. ASCO Annual Meeting 2006,
23. Kaplan FM, Shao Y, Mayberry MM, Aplin AE. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene 2011, 30:366-371. 10.1038/onc.2010.408, 20818433.
24. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010, 23:190-200. 10.1111/j.1755-148X.2010.00685.x, 2848976, 20149136.
25. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 2012, 11:909-920. 10.1158/1535-7163.MCT-11-0989, 22389471.
26. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703. 10.1056/NEJMoa1210093, 3549295, 23020132.
27. Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118(16):4014-23. 10.1002/cncr.26724, 3310961, 22180178.
28. Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, Hansson J, Lundeberg J. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006, 16:471-478. 10.1097/01.cmr.0000232300.22032.86, 17119447.
29. Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, et al. A landscape of driver mutations in melanoma. Cell 2012, 150:251-263. 10.1016/j.cell.2012.06.024, 3600117, 22817889.
30. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012, 44:1006-1014. 10.1038/ng.2359, 3432702, 22842228.
31. Surviladze Z, Waller A, Wu Y, Romero E, Edwards BS, Wandinger-Ness A, Sklar LA. Identification of a small GTPase inhibitor using a high-throughput flow cytometry bead-based multiplex assay. J Biomol Screen 2010, 15:10-20. 10.1177/1087057109352240, 3433230, 20008126.
32. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, Fauber BP, Pan B, Malek S, Stokoe D, Ludlam MJ, Bowman KK, Wu J, Giannetti AM, Starovasnik MA, Mellman I, Jackson PK, Rudolph J, Wang W, Fang G. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A 2012, 109:5299-5304. 10.1073/pnas.1116510109, 3325706, 22431598.
33. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem 2011, 3:1787-1808. 10.4155/fmc.11.121, 3347641, 22004085.
34. Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012, 18:555-567. 10.1158/1078-0432.CCR-11-1491, 3549298, 22048237.
35. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901. 10.1016/S0140-6736(12)60398-5, 22608338.
36. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14:249-256. 10.1016/S1470-2045(13)70024-X, 23414587.